Author Details :
Volume : 6, Issue : 1, Year : 2021
Article Page : 62-66
The fungal infection clinically referred as mycormycosis also zygomycosis are common infections to human where causative agent i.e., Mucoromycotina is member of mucorales. The causative agent mucoromycotina habitats in soil and decaying organic matter. The mycoromycotina infection remains associated with wide array of human disease including septic arthritis, dialysis-associated peritonitis, renal disorders, gastritis, and pulmonary diseases. These infections are closely associated with mucous layer of skin precisely cutaneous layer. These infections are also seen in clinical samples to nasal and upper respiratory tract. The higher prevalence of nasal cerebral i.e. rhinocerebral mycormycosis reported in case of immune compromised patients that trigger colonization of R. oryzae. In chronic state as infection reaches to lower respiratory tract these infection are difficult to diagnose and treat due to lack of precise methods. It has been reported neutropenia patients are more prone for mycormycosis infections due to extensive use of chemotherapy resulting impaired immunity. In recent time, necrotizing pneumonia is major symptoms reported in case of pulmonary mycormycosis. The common antifungal medication based clinical symptoms such as dyspnea, congestion and chest pain with rise in body temperature itraconozole is highly recommended. Further, a combination of antifungal and antimicrobial agents had shown a significant higher clinical recovery in mycormycosis case.
Keywords: Amphotericin B, Hyponatremia, Itraconazole, Voriconazole, Oral Posaconazole.
How to cite : Chennamchetty V K, Adimulapu S , Kola B P, Padua M D, Ambika C, Rao M V R, Post-COVID pulmonary mucormycosis- A case report. IP Indian J Immunol Respir Med 2021;6(1):62-66
Copyright © 2021 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)